[1] |
Zhao YH,Feng HL,Zheng LH,et al.Progress on osteosarcoma pathogensis[J].Zhong Liu Fang Zhi Yan Jiu,2014,41(3):283-6.[赵 亚恒,冯和林,郑丽华,等.骨肉瘤发病机制的研究进展[J].肿瘤防 治研究,2014,41(3):283-6.]
|
[2] |
Hughes DP. Strategies for the targeted delivery of therapeutics for osteosarcoma[J]. Expert Opin Drug Deliv,2009,6(12):1311-21.
|
[3] |
Lai SQ, Xu M. Antineoplastic lobaplatin[J]. Shi Jie Lin Chuang Yao Wu,2005,26(5):315. [赖树清,须媚. 抗肿瘤药洛铂[J]. 世界 临床药物,2005,26(5):315.]
|
[4] |
Zhao S, Yang GL, Lv YQ, et al. The initial approach to the effect of lobaplatin on lung cancer cell line A549[J]. Lin Chuang Zhong Liu Xue Za Zhi,2011,16(1):14-8. [赵姗,杨光磊,吕英谦, 等. 洛铂对肺癌A549细胞作用的初步探讨[J]. 临床肿瘤学杂 志,2011,16(1):14-8.]
|
[5] |
Yang LQ, Qin SK, Qian J, et al. Clinical study of lobaplatin combined with fluorouracil and leucovorin for advanced esophageal carcinoma [J]. Lin Chuang Zhong Liu Xue Za Zhi,2006, 11 (12):895-7,900. [杨柳青, ??叔逵, 钱军,等.洛铂联合醛氢叶 酸、氟尿嘧啶治疗晚期食管癌的临床研究[J]. 临床肿瘤学杂 志,2006,11(12):895-7,900.]
|
[6] |
Rougraff BT,Kneisl JS,Simon MA,et al.Skeletal metastases of unknown origin.A prospective study of a diagnostic strategy[J].J Bone Joint Surg Am,1993,75(9):1276-81.
|
[7] |
Takayama S,Sato T,Krajewski S,et al.Cloing and functional analysis of AG-1:a novel Bcl-2-binding protein with anti-cell death activity[J].Cell,1995,80(2):279-84.
|
[8] |
Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy[J]. Expert Opin Ther Targets,2013,17(1):61-75.
|
[9] |
Yin QH, Yan FX, Zu XY, et al. Anti-proliferative and proapoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2[J]. Cytotechnology,2012,64(1):43-51.
|
[10] |
Liang CZ, Zhang JK, Shi Z, et al. Matrine induces caspasedependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/Fasl and downregulation of Bcl-2[J]. Cancer chemother and pharmacol, 20 12,69(2):317-31.
|
[11] |
Chang C, Zhu Y, Tang X, et al. The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture[J]. Mol Biol Rep,2011,38(1):163-9.
|